相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Feng-Hua Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis
Jaimin J. Patel et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study
Tong Xie et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P. D'Angelo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence
Ceyda Sancakli Usta et al.
INFECTIOUS AGENTS AND CANCER (2020)
Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy
Antoine Marchand et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
HPV Vaccination and the Risk of Invasive Cervical Cancer
Jiayao Lei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai et al.
BIOMARKER RESEARCH (2020)
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients
Zhen Lin et al.
FRONTIERS IN ONCOLOGY (2020)
Biological and clinical aspects of HPV-related cancers
Klaudia Anna Szymonowicz et al.
CANCER BIOLOGY & MEDICINE (2020)
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Seok-Jin Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy
Arash Salmaninejad et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Advances in the Management of HPV-Related Oropharyngeal Cancer
F. De Felice et al.
JOURNAL OF ONCOLOGY (2019)
Immune checkpoint inhibitors in the treatment of virus-associated cancers
Peipei Gao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Immunotherapy for head and neck cancer: where are we now and where are we going?
Joshua M. Bauml et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Impact of HPV Infection on the Immune System in Oropharyngeal and Non-Oropharyngeal Squamous Cell Carcinoma: A Systematic Review
Jerome R. Lechien et al.
CELLS (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers
Jitwadee Inthagard et al.
CLINICAL SCIENCE (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
The Changing Epidemiology of Primary Liver Cancer
Jessica L. Petrick et al.
CURRENT EPIDEMIOLOGY REPORTS (2019)
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Brigette B. Y. Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Immunotherapy against cancer-related viruses
Haruko Tashiro et al.
CELL RESEARCH (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity
Chaoqi Liu et al.
MOLECULAR MEDICINE REPORTS (2017)
Epstein-Barr virus infection and nasopharyngeal carcinoma
Sai Wah Tsao et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2017)
Oncogenic Role of Tumor Viruses in Humans
Nimrah Akram et al.
VIRAL IMMUNOLOGY (2017)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Update on Epstein-Barr virus and gastric cancer
Aya Shinozaki-Ushiku et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Louisa Mezache et al.
MODERN PATHOLOGY (2015)
Hepatitis C virus-induced hepatocellular carcinoma
Nicolas Goossens et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2015)
HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of US Veterans With HCV
Fasiha Kanwal et al.
HEPATOLOGY (2014)
Immunotherapy of hepatocellular carcinoma Unique challenges and clinical opportunities
Angela D. Pardee et al.
ONCOIMMUNOLOGY (2012)
Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections
Oludare A. Odumade et al.
CLINICAL MICROBIOLOGY REVIEWS (2011)
EBV-associated gastric carcinoma in high- and low-incidence areas for nasopharyngeal carcinoma
T. Boysen et al.
BRITISH JOURNAL OF CANCER (2009)
Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: A meta-analysis
Ju-Han Lee et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
The human papillomavirus E7 oncoprotein
Margaret E. McLaughlin-Drubin et al.
VIROLOGY (2009)
Oncogenesis and transforming viruses: the hepatitis B virus and hepatocellularcarcinoma - the etiopathogenic link
Alvin T. C. Lee et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus
Moon-Sung Chang et al.
CLINICAL CANCER RESEARCH (2006)
Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis
D. Kremsdorf et al.
ONCOGENE (2006)
Mechanisms of disease - Persistence of the Epstein-Barr virus and the origins of associated lymphomas
DA Thorley-Lawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
